Answers are grounded in this paper and cite their sources.
U.S. researchers lack appropriate access to commercially available cannabis products for clinical trials. Meanwhile, patients continue to use state-sanctioned products marketed as medicines in the absence of evidence to support their benefits or define their harms.
No takes yet. Share an insight, caveat, or question.
Zarrabi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: